POTASSIUM CHANNEL INHIBITORS AS THERAPEUTIC AGENTS IN LYMPHOMA AND LEUKAEMIA Russian patent published in 2014 - IPC A61K31/554 A61K31/21 A61K31/201 A61K31/138 A61P35/02 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to molecular biology, molecular genetics and biotechnology, and can be used in medicine, as well as in agriculture and industrial biotechnology for the development of a fundamentally new approach to antileukaemic therapy with the use of low-molecular compounds against specific molecular targets, which include molecules of subunits of voltage-gated potassium channels of the family Kv. What is presented is using potassium channel inhibitors specified in diltiazem hydrochloride, anandamide (arachidonylethanolamide), verapamil hydrochloride, linoleic acid as an agent for enhancing the apoptosis of tumour B-cells in chronic lymphatic leukaemia. The technical effect is achieved by the fact that the low-molecular compounds are used to simulate the inhibitory effect of the KCNRG protein, which inhibits the normal assembly of potassium channel proteins by binding to the region responsible for their tetramerisation and thereby suppressing the channel activity.

EFFECT: creating the potassium channel inhibitors used as an agent to induce the apoptosis of tumour B-cells in chronic lymphatic leukaemia.

2 dwg, 3 tbl